Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Andrew Lee

Infectious Disease Oakhurst, NJ Medical Doctor

NPI 1619904216 CMS profile 255048

1912 State Route 35, Suite 101, Oakhurst, NJ 07755

Open in the dashboard

General payments

$3,977

247 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Andrew Lee of Oakhurst, NJ is reported in the CMS Open Payments database as having received $3,977 across 247 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $604 32
2024 General $713 44
2023 General $566 38
2022 General $583 48
2021 General $525 41
2020 General $281 13
2019 General $705 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew Lee
  • Infectious Disease median
  • Middle half of Infectious Disease
  • National median

In program year 2025, general payments to Andrew Lee were reported at $604. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.

Show as a table
Year Andrew Lee Infectious Disease median Middle half National median
2019 $705 $190 $60–$862 $163
2020 $281 $124 $32–$606 $114
2021 $525 $148 $38–$905 $132
2022 $583 $166 $50–$834 $149
2023 $566 $171 $57–$787 $160
2024 $713 $176 $52–$752 $164
2025 $604 $188 $57–$766 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Gilead Sciences, Inc. $721 61 payments
  2. Merck Sharp & Dohme Corporation $647 30 payments
  3. ViiV Healthcare Company $553 29 payments
  4. Insmed, Inc. $325 22 payments
  5. AbbVie, Inc. $287 18 payments
  6. Paratek Pharmaceuticals, Inc. $238 17 payments
  7. Aimmune Therapeutics, Inc. $222 13 payments
  8. GlaxoSmithKline, LLC. $212 17 payments
  9. Melinta Therapeutics, Inc. $184 12 payments
  10. Smith+Nephew, Inc. $111 1 payment
  11. Other $476 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,922 244 payments
  2. Education $55 3 payments
Products named General payments · program years 2019–2025
  1. DIFICID $513 22 payments
  2. DOVATO $428 21 payments
  3. Arikayce $325 22 payments
  4. PIFELTRO $263 18 payments
  5. NUZYRA $238 17 payments
  6. DELSTRIGO $227 16 payments
  7. VOWST $222 13 payments
  8. ZINPLAVA $220 2 payments
  9. DALVANCE $183 11 payments
  10. ZERBAXA $164 10 payments
  11. Other $2,161 133 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

709

Median for Infectious Disease: 268

Drug cost

$603,611

Median for Infectious Disease: $217,595

Branded share of claims

66.4%

Median for Infectious Disease: 45.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 33 $140,452
Triumeq Abacavir/Dolutegravir/Lamivudi Brand 36 $134,857
Dovato Dolutegravir Sodium/Lamivudine Brand 36 $105,139
Genvoya Elviteg/Cob/Emtri/Tenof Alafen Brand 12 $55,369
Symtuza Darunavir/Cob/Emtri/Tenof Alaf Brand 12 $50,060
Descovy Emtricitabine/Tenofov Alafenam Brand 13 $28,137
Tivicay Dolutegravir Sodium Brand 11 $24,432
Pifeltro Doravirine Brand 11 $19,473
Efavirenz-Emtric-Tenofov Disop Efavirenz/Emtricit/Tenofovr Df Brand 13 $19,373
Daptomycin Generic 25 $6,801

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,546 Part D prescribers listed as Infectious Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$321,666

Medicare's payments for the services billed

Medicare patients

1,593

Average age 78

Services billed

4,419

809 women, 784 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 64%
Arthritis 64%
Heart failure 55%
Chronic kidney disease 54%
Diabetes 52%
Atrial fibrillation 50%
Depression 46%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUZYRA
  • Paratek Pharmaceuticals, Inc. $55
$55 — —
DOVATO
  • ViiV Healthcare Company $48
$48 36 —
CABENUVA
  • ViiV Healthcare Company $31
$31 — —
REBYOTA
  • Ferring Pharmaceuticals Inc. $23
$23 — —
DIFICID
  • Merck Sharp & Dohme Corporation $22
$22 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

247 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Infectious Disease in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record